Phase 3 trial of REX-001 bone marrow cell therapy in diabetic patients with no-option chronic limb-threatening ischaemia, stopped early for lack of efficacy at interim analysis: ulcer healing or Rutherford improvement in 28.6% vs 27.3% with placebo (32 completed).
RCTn = 32
Peeters et al. The Premature Termination of the Phase III SALAMANDER Trial of REX-001, an Autologous Bone Marrow Cell Therapy, for Chronic Limb Ischemia in Diabetic Patients: Insights and Outcomes